Muhammad UmairMushtaqMD

PubMed

• Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation.
  Muhammad Kashif Amin, Zahra Mahmoudjafari, Matthew McGuirk, Shaun DeJarnette, Moazzam Shahzad, Polina Bellman, Joe Al-Ramahi, Jawad Noor, Abhinav Vyas, Nausheen Ahmed,...> ;Transfusion. 2024 Jun 7
• Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
  Muhammad Fareed Khalid, Muhammad Kashif Amin, Ali H Mushtaq, Atif Butt, Iqra Anwar, Moazzam Shahzad, Mohammad Ammad-Ud-Din, Usman Ilyas, Sibgha Gull Chaudhary, Naushee...> ;Hematology/oncology and Stem Cell Therapy. 2024 Mar 22
• Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
  Matthew McGuirk, Moazzam Shahzad, Muhammad Kashif Amin, Muhammad Atif Khan, Polina Bellman, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Forat Lutfi, Nausheen Ahmed, Ra...> ;Transplant Immunology. 2024 Jun 1
• 3 citations
  Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response byF-FDG PET/CT Imaging Following CAR-T Therapy.
  Lutfi, F., Goloubeva, O., Kowatli, A., Gryaznov, A., Kim, D., Dureja, R., Margiotta, P., Matsumoto, L., Bukhari, A., Ahmed, N., Mushtaq, M., Law, J., Lee, S., Kocoglu,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Oct 1
• 3 citations
  "Waitlist mortality" is high for myeloma patients with limited access to BCMA therapy.
  Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, Rajat Bansal, Haitham AbdelHakim, Sarah Bromert, Allison Appenfeller, Batool Abu Ghazal, Anurag Singh, Sunil Ab...> ;Frontiers in Oncology. 2023 Jan 1
• 6 citations
  Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
  Mushtaq, M., Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, David L Porter, Sunita D Nasta, Jamie Brower, Veronika Bachanova, Marie Hu, Loretta J Nastoupil, O...> ;Transplantation and Cellular Therapy. 2023 Jul 1
• 2 citations
  Poor hospitalization outcomes in patients undergoing allogeneic hematopoietic stem cell transplant with hospital acquired influenza infection.
  Mohammad Ammad Ud Din, Ali Jaan, Moazzam Shahzad, Hania Liaqat, Joseph McGuirk, Muhammad Umair Mushtaq> ;Transplant Infectious Disease. 2023 Jun 1
• 8 citations
  Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
  Moazzam Shahzad, Andrea Nguyen, Ali Hussain, Mohammad Ammad-Ud-Din, Muhammad Salman Faisal, Ezza Tariq, Fatima Ali, Atif Butt, Iqra Anwar, Sibgha Gull Chaudhary, Forat...> ;Frontiers in Immunology. 2023 Jan 1
• 4 citations
  Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute...
  Moazzam Shahzad, Ali Hussain, Ezza Tariq, Iqra Anwar, Muhammad S Faisal, Leena Syed, Alvina Karam, Sibgha Gull Chaudhary, Nausheen Ahmed, Rajat Bansal, Sharad Khurana,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Mar 1
• Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
  Moazzam Shahzad, Sibgha Gull Chaudhary, Ezza Tariq, Ali Hassan Mushtaq, Iqra Anwar, Nausheen Ahmed, Rajat Bansal, Forat Lutfi, Ramesh Balusu, Haitham Abdelhakim, Abdul...> ;Leukemia & Lymphoma. 2023 Feb 1
• 11 citations
  Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
  Moazzam Shahzad, Ezza Tariq, Sibgha Gull Chaudhary, Iqra Anwar, Qamar Iqbal, Huda Fatima, Haitham Abdelhakim, Nausheen Ahmed, Ramesh Balusu, Peiman Hematti, Anurag K S...> ;Leukemia & Lymphoma. 2022 Dec 1
• 40 citations
  Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.
  Nausheen Ahmed, Moazzam Shahzad, Ernie Shippey, Rajat Bansal, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Muhammad Salman Faisal, Marc Hoffmann, Al-Ola Abdallah, Clin...> ;Transplantation and Cellular Therapy. 2022 Jul 1
• Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis.
  Razwana Khanam, Moazzam Shahzad, Sibgha Gull Chaudhary, Fatima Ali, Zunairah Shah, Pranali S Pachika, Zahoor Ahmed, Asmi Chattaraj, Adeel Masood, Nausheen Ahmed, Rajat...> ;Leukemia & Lymphoma. 2022 Nov 1
• 2 citations
  Top 100 Cited Articles on Clinical Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis.
  Moazzam Shahzad, Sibgha Gull Chaudhary, Iqra Anwar, Muhammad Arslan, Zehra Naseem, Naira T Fatima, Sakina Abbas, Tayyaba Ali, Raheel S Siddiqui, Peiman Hematti, Sunil ...> ;Frontiers in Medicine. 2022 Jan 1
• 4 citations
  Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients.
  Qamar J Khan, Cory R Bivona, Ben Liu, Maggie Nelson, Grace A Martin, Muhammad Umair Mushtaq, Priyanka Sharma, Natalie R Streeter, Marc Hoffmann, Gary C Doolittle, Cunc...> ;Bone Marrow Transplantation. 2022 Jun 1
• 6 citations
  Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies.
  Raheel Sufian Siddiqui, Sibgha Gull Chaudhary, Moazzam Shahzad, Iqra Anwar, Ali Hussain, Nausheen Ahmed, Sunil Hari Abhyankar, Leyla Shune, Peiman Hematti, Heather Mal...> ;Leukemia & Lymphoma. 2022 Jul 1
• 2 citations
  Functional characterization of NPM1-TYK2 fusion oncogene.
  Sudhakiranmayi Kuravi, Riley W Baker, Muhammad Umair Mushtaq, Irfan Saadi, Tara L Lin, Carolyn J Vivian, Anusha Valluripalli, Sunil Abhyankar, Siddhartha Ganguly, Wei ...> ;NPJ Precision Oncology. 2022 Jan 18
• 26 citations
  Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
  Moazzam Shahzad, Sibgha Gull Chaudhary, Muhammad U Zafar, Maha A Hassan, Ali Hussain, Fatima Ali, Iqra Anwar, Mamoon Ahmed, Nausheen Ahmed, Sharad Khurana, Muhammad A ...> ;Transplant Infectious Disease. 2022 Apr 1
• 1 citations
  Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
  Muhammad Umair Mushtaq, Moazzam Shahzad, Amna Y Shah, Sibgha Gull Chaudhary, Muhammad U Zafar, Iqra Anwar, Karun Neupane, Ayesha Khalid, Nausheen Ahmed, Rajat Bansal, ...> ;Frontiers in Immunology. 2022 Jan 1
• 6 citations
  Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.
  Muhammad Umair Mushtaq, Moazzam Shahzad, Ezza Tariq, Qamar Iqbal, Sibgha Gull Chaudhary, Muhammad U Zafar, Iqra Anwar, Nausheen Ahmed, Rajat Bansal, Anurag K Singh, Su...> ;Frontiers in Oncology. 2022 Jan 1
• 5 citations
  Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.
  Moazzam Shahzad, Sibgha Gull Chaudhary, Abdul Basit, Connor Thellman, Liza Rodriguez, Sunil H Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq> ;Transplant Immunology. 2022 Feb 1
• 16 citations
  Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
  Moazzam Shahzad, Raheel S Siddiqui, Iqra Anwar, Sibgha Gull Chaudhary, Tayyaba Ali, Masooma Naseem, Tehniat F. Ahmed, Zahoor Ahmed, Sharad Khurana, Nausheen Ahmed, Ram...> ;Transplantation and Cellular Therapy. 2021 Oct 1
• 37 citations
  Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
  Muhammad Umair Mushtaq, Moazzam Shahzad, Sibgha Gull Chaudhary, Mary Luder, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Ramesh Balusu, Shaun DeJarnette, Clint Di...> ;Transplantation and Cellular Therapy. 2021 Sep 1
• 8 citations
  Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
  Vivek Subbiah, Sudhakiranmayi Kuravi, Siddhartha Ganguly, Danny R. Welch, Carolyn J. Vivian, Muhammad Umair Mushtaq, Aparna Hegde, S. Iyer, Amini Behrang, Siraj M. Ali...> ;ESMO Open. 2021 Aug 1
• 1 citations
  Simultaneous acute myeloid leukemia, multiple myeloma, and amyloidosis.
  Muhammad Umair Mushtaq, Daniel R. Matson> ;Blood. 2019 Oct 10
• Join now to see all

Abstracts/Posters

• The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
  Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S375-S376, 2/2024
• The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
  Atallah R, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S373-S374, 2/2024
• The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
  Khaliq A, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S208, 2/2024
• Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure
  Lutfi F, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S229, 2/2024
• BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple Myeloma after CAR-T?
  Rashid A, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S194-S195, 2/2024
• Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
  Soomro MA, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S373, 2/2024
• Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest
  Tabak C, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S323, 2/2024
• VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular Therapy in Triple Class Relapsed/Refractory Multiple Myeloma
  Venkatesh P, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S389-S390, 2/2024
• A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients
  Wesson W, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S207-S208, 2/2024
• Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
  Amin MK … Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S241-42, 2/2024
• Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Ce...
  Shahzad M … Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S172, 2/2024
• Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myelo...
  Shah N, et al. Among other authors: Mushtaq MU, Transplantation and Cellular Therapy. 2024; 30: S225-S226, 2/2024
• BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma
  Rashid A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6801, 12/2023
• Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma
  Wesson W, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6914, 12/2023
• Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians
  Atallah R, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6678, 12/2023
• Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma
  Venkatesh P, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6694, 12/2023
• Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure
  Lutfi F, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6916, 12/2023
• Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy
  Soomro MA, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 6900, 12/2023
• Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation
  Al-Ramahi J … Mushtaq MU, Blood. 2023; 142 (S1): 7028, 12/2023
• The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
  Atallah R, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 3327, 12/2023
• Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics
  Snyder J, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 1985, 12/2023
• Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant
  Mammadzadeh A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 4727, 12/2023
• The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
  Khaliq A, et al. Among other authors: Mushtaq MU, Blood. 2023; 142 (S1): 2344, 12/2023
• Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
  Amin M … Mushtaq MU, Blood. 2023; 142 (S1): 2242, 12/2023
• Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Ce...
  Shahzad M … Mushtaq MU, Blood. 2023; 142 (S1): 3523, 12/2023
• Join now to see all

Lectures

• Highlights of American Society of Hematology Annual Meeting 2023. University of Kansas Cancer Center ASH Review 
  Kansas City, KS - 1/2024
• Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients. Grand Rounds Speaker at the University of Kansas Me... 
  Kansas City, KS - 4/2022
• Graft failure and graft rejection. American Society of Transplantation & Cellular Therapy Fall Clinical Education Conference (ASTCT CEC) 
  Virtual - 9/2021
• Highlights of American Society of Hematology Annual Meeting 2020. University of Kansas Cancer Center ASH Review 
  Kansas City, KS - 1/2021
• Highlights of American Society of Hematology Annual Meeting 2019. University of Wisconsin Carbone Cancer Center Grand Rounds 
  Madison, WI - 1/2020
• Matrix-based biomarkers for cancer immunotherapy. Guest Speaker at University of Kansas, Kansas City, KS (08/2019), University of Arizona, Tucson, AZ (08/2019), Wake F... 
  8/2019
• Highlights of American Society of Hematology Annual Meeting 2018. University of Wisconsin Carbone Cancer Center Grand Rounds 
  Madison, WI - 2/2019
• Join now to see all